drugset

drugset / Trial / NCT05672888

Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

NCT05672888 ↗

Phase 2 Unknown 60 enrolled First Affiliated Hospital of Zhejiang University

RandomizedParallel-groupDouble-blindTreatment

Summary

This was a randomized, double-blind, placebo-controlled parallel study.

Timeline

Start: 2023-03
Primary completion: 2024-01
Completion: 2024-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Jaktinib	Unknown	100 mg	Oral

Indications